BioDuro, LLC, a contract research organization (CRO) focused on outsourced turnkey discovery and development services, has completed its merger with Formex to become an end-to-end solution provider for integrated drug discovery and development, active pharmaceutical ingredient synthesis and optimization, formulation and cGMP manufacture of drug products.

BioDuro, a US owned research and development contractor founded in 2005, with laboratories in San Diego, Beijing and Shanghai, is a full-service preclinical research and clinical development service provider that offers discovery and development solutions from lead identification and optimization through to dosage form development and manufacturing. Until the company’s recent merger with Formex, BioDuro focused primarily on preclinical discovery, and early clinical development of pharmaceuticals.

With the addition of Formex, customers gain access to a 44,000 square-foot, purpose-built cGMP manufacturing facility in San Diego, with expertise in formulation, development, and manufacture of drug products.

BioDuro’s global operations include a 100,000 square-foot facility in Beijing, focused largely on biosimilars, synthetic, medicinal and computational chemistry, formulation development and analytical support for conducting bioequivalence studies in support of CFDA filings, and a 92,000 square-foot facility in Shanghai, which houses BioDuro’s drug screening, DMPK, integrated biology and a turnkey 18,000 square-foot vivarium, as well as good laboratory practices (GLP), bioanalysis, PK/PD, biomarker and translational research. /p>

Source: BioDuro